• No image available for this medication

    • BALVERSA

    • QTY 56
    • 3 MG
    • Tablet

ERDAFITINIB (ER da FI ti nib) treats urothelial cancer. It works by targeting proteins in cancer cells and stopping the cancer cells from growing.

BALVERSA Lifestyle Interactions

  • Erdafitinib 3mg, Oral tablet

    • Interaction: Grapefruit juice
    • Severity: Major
    • Notes for Consumers: Do not take Erdafitinib with Grapefruit Juice without talking to your health care professional. Side effects from Erdafitinib may get worse. Contact your health care provider if you experience mouth sores, diarrhea, unusually weak or tired, changes in vision, or other new or unusual side effects.
    • Notes for Professionals: Advise patients to avoid grapefruit juice while taking erdafitinib due to increased erdafitinib exposure. Erdafitinib is a substrate of CYP2C9 and CYP3A4. Grapefruit juice is a moderate CYP2C9 inhibitor and a strong CYP3A4 inhibitor. The mean ratios for the Cmax and AUC of erdafitinib were 105% and 134%, respectively, when coadministered with another strong CYP3A4 inhibitor.

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.